1832 Asset Management L.P. Has $85.56 Million Stock Position in Boston Scientific Corporation $BSX

Key Points

• 1832 Asset Management L.P. increased its stake in Boston Scientific Corporation by 11.1%, acquiring an additional 84,585 shares, bringing its total holdings to 848,147 shares valued at approximately $85.6 million.
• Institutional investors now own 89.07% of Boston Scientific's stock, with significant increases in holdings from major firms like Price T Rowe Associates, which raised its stake by 18.6%.
• Boston Scientific reported a strong quarterly performance, exceeding analysts' expectations with $0.75 EPS and revenues of $5.06 billion, marking a 22.8% increase compared to the previous year.

1832 Asset Management L.P. grew its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 11.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 848,147 shares of the medical equipment provider's stock after acquiring an additional 84,585 shares during the period. 1832 Asset Management L.P. owned 0.06% of Boston Scientific worth $85,561,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Y.D. More Investments Ltd bought a new stake in Boston Scientific in the first quarter worth $27,000. Investment Management Corp VA ADV bought a new stake in shares of Boston Scientific in the fourth quarter valued at about $25,000. Colonial Trust Co SC lifted its stake in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 260 shares during the period. Sunbeam Capital Management LLC bought a new stake in shares of Boston Scientific in the fourth quarter valued at about $26,000. Finally, Ameriflex Group Inc. bought a new position in Boston Scientific during the fourth quarter worth about $31,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Down 0.4%

BSX stock traded down $0.45 during midday trading on Wednesday, hitting $105.94. The company's stock had a trading volume of 5,686,959 shares, compared to its average volume of 7,517,284. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a twelve month low of $79.03 and a twelve month high of $108.94. The company's fifty day moving average price is $104.27 and its 200 day moving average price is $102.15. The stock has a market capitalization of $156.98 billion, a P/E ratio of 63.06, a PEG ratio of 2.53 and a beta of 0.66.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter last year, the firm posted $0.62 EPS. The company's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

BSX has been the subject of a number of analyst reports. Leerink Partnrs upgraded shares of Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Needham & Company LLC reissued a "buy" rating and set a $115.00 price target on shares of Boston Scientific in a research note on Wednesday, May 28th. Leerink Partners started coverage on shares of Boston Scientific in a research note on Monday, June 16th. They set an "outperform" rating and a $118.00 price target on the stock. Raymond James Financial raised their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 24th. Finally, UBS Group increased their target price on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of "Buy" and an average target price of $117.50.

Insider Buying and Selling at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company's stock, valued at approximately $18,659,923.46. The trade was a 21.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director directly owned 18,479 shares of the company's stock, valued at $1,959,328.37. The trade was a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 345,029 shares of company stock worth $35,976,603 in the last ninety days. Insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.